healthneutral
CAR-T Therapy Challenges: The ANXA1 Connection
Sunday, March 9, 2025
The cancer cells with high ANXA1 levels were found in patients who had not even received CAR-T therapy. This suggests that ANXA1 might play a role in making cancer cells resistant to treatment. Lab tests showed that high ANXA1 levels helped the cancer cells grow and made the CAR-T cells less effective. When ANXA1 was blocked, the cancer cells grew less. This was also seen in mouse models, where blocking ANXA1 helped reduce the number of cancer cells that escaped the CAR-T cell attack.
So, ANXA1 could be a new target for treating MM, especially for patients who relapse after CAR-T therapy. By targeting ANXA1, doctors might be able to make CAR-T therapy more effective. This could help more patients achieve long-term remission. However, more research is needed to fully understand how ANXA1 works and how best to target it.
It's important to note that cancer is complex. Many factors can contribute to relapse. Understanding these factors can help improve treatments. This study provides new insights into what might be happening when MM relapses after CAR-T therapy. It also suggests a potential new target for treatment.
Actions
flag content